News from CROI 2011

aidsmap news from CROI 2011

Modellers examine the cost-effectiveness of PrEP in Africa

As well as two models of how PrEP/microbicides would impact on HIV prevalence and incidence in a southern African context (see Forecasters agree PrEP/microbicides could cut HIV infections

Published
03 March 2011
By
Gus Cairns
Forecasters agree PrEP/microbicides could cut HIV infections in South Africa

Several presentations at the Eighteenth Conference on Retroviruses and Opportunistic Infections this week used mathematical modelling to forecast the impact of adopting oral pre-exposure prophlyaxis (PrEP) or a

Published
03 March 2011
By
Gus Cairns
Once-daily raltegravir found inferior to twice-daily dosing

Once-daily dosing of the integrase inhibitor raltegravir (Isentress) was found to be inferior to twice-daily dosing for treatment-naive patients in the QDMRK study, even though most people receiving

Published
03 March 2011
By
Liz Highleyman
Is HIV drug resistance spreading? Early warning signals say 'yes'

Signals warning of the transmission of drug-resistant HIV are growing in low- and middle-income countries, and governments should step up surveillance efforts as they scale up treatment, experts

Published
03 March 2011
By
Keith Alcorn
Telaprevir works well for people with HIV/HCV co-infection

The experimental hepatitis C virus (HCV) protease inhibitor telaprevir, used with pegylated interferon plus ribavirin, produced good virological response in the first study of HIV/HCV co-infected individuals, according to

Published
02 March 2011
By
Liz Highleyman
First pills-versus-gel trial finds US women prefer oral PrEP

The first head-to-head trial directly comparing the acceptability of tenofovir pills and tenofovir microbicide gel amongst HIV-negative women has found that, while African women liked both products

Published
02 March 2011
By
Gus Cairns
Does immune reconstitution contribute to ART-related bone loss?

Immune recovery and T-cell restoration may play a key role in bone loss that occurs very soon after starting antiretroviral therapy, according to a small study presented

Published
02 March 2011
By
Liz Highleyman
New data from PrEP study shed light on adherence, bone mineral loss and resistance

Near-perfect adherence to oral pre-exposure prophylaxis – taking HIV drugs to prevent HIV – may be achievable in the right settings, the Eighteenth Conference on Retroviruses and

Published
02 March 2011
By
Gus Cairns
Abacavir not linked to increased risk of heart attack, reports US FDA

The US Food and Drug Administration has found no evidence of an association between abacavir treatment and increased risk of myocardial infarction (heart attack) in a meta-analysis of

Published
02 March 2011
By
Keith Alcorn
Decreased limb muscle and increased abdominal fat linked to higher mortality in people with HIV

HIV-positive people who lose muscle mass in their arms and legs whilst gaining abdominal fat have a higher likelihood of death, according to findings from the FRAM

Published
02 March 2011
By
Liz Highleyman
← Prev123Next →

The search for a cure

Zinc finger gene therapy produces HIV-resistant CD4 T-cells.

Read this news story >

Subscribe now

Email bulletins from NAM

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.